Liver transplantation for malignancy: Current treatment strategies and future perspectives

Table 4 Liver transplantation for hepatic metastases of neuroendocrine tumors: reports with > 100 patients

Database	Author	Year	Year of LT	n	Age of patients	Female	Follow-up	Overall survival in %			DFS in %			LDLT	Recurrence
								1 yr	3 yr	5 yr	1 yr	3 yr	5 yr
Europe	LeTreut	2013	1982-2009	213	Mean 46 yr	46%	Mean 56 ± 49 mo	81	65	52	65	40	30	6%	53%
UNOS	Gedaly	2011	1988-2008	150	Mean 45 yr	44%	Mean 36.8 mo	81	65	49	NR	NR	32	7%	NR
UNOS	N'Guyen	2011	1988-2011	194	Mean 45 yr	46%	NR	80	61	49	NR	NR	NR	NR	NR
UNOS	N‘Guyen	2011	2002-2011	110	Mean 45 yr	46%	NR	85	65	58	NR	NR	NR	NR	NR
France	LeTreut	2008	1989-2005	85	Mean 46 yr	46%	Mean 46 ± 47 mo	72	59	47	56	37	20	2%	NR
Review	Lehnert	1998	1981-1997	103	Median 48 yr	50%		Calculated 60		Calculated 47			Calculated 24	NR	40%

LT: Liver transplantation; DFS: Disease-free survival; LDLT: Living-donor liver transplantation; NR: Not reported; UNOS: United Network for Organ Sharing.